Tumour necrosis factor signalling in health and disease.
Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, McDermott M. · 2019
Read Tumour necrosis factor signalling in health and disease. by Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, McDermott M. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6352924.txt.
Introduction
Holbrook and co-authors review tumour necrosis factor signaling in health and disease. Their review appeared in F1000Research. TNF is a master inflammatory signal in the body. It shapes the first, fast phase of immune defense. It also drives cell growth and programmed death. Two receptors pass its messages into cells.
The wider TNF family holds 19 ligands and 29 receptors. Over forty years of work mapped their roles. The same signals that defend us can go wrong. TNF is implicated in rheumatoid arthritis. It also features in Crohn's disease and a spine condition. Drugs that block TNF grew from this knowledge. The review sums the pathways and their disease links.
Catalog record
| CREATOR | Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, McDermott M. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Tumour necrosis factor signalling in health and disease By Jonathan Holbrook, Samuel Lara-Reyna, Heledd Jarosz-Griffiths, Michael F. McDermott Published in: F1000Research DOI: 10.12688/f1000research.17023.1 ABSTRACT The master pro-inflammatory cytokine, tumour necrosis factor (TNF), has been shown to modulate multiple signalling pathways, with wide-ranging downstream effects. TNF plays a vital role in the typical immune response through the regulation of a number of pathways encompassing an immediate inflammatory reaction with significant innate immune involvement as well as cellular activation with subsequent proliferation and programmed cell death or necrosis. As might be expected with such a broad spectrum of cellular effects and complex signalling pathways, TNF has also been implicated in a number of disease states, such as rheumatoid arthritis, ankylosing spondylitis, and Crohn’s disease. Since the time of its discovery over 40 years ago, TNF ligand and its receptors, TNF receptor (TNFR) 1 and 2, have been categorised into two complementary superfamilies, namely TNF (TNFSF) and TNFR (TNFRSF), and 19 ligands and 29 receptors have been identified to date. There have been significant advances in our understanding of TNF signalling pathways in the last decade, and this short review aims to elucidate some of the most recent advances involving TNF signalling in health and disease. INTRODUCTION Since the identification of tumour necrosis factor (TNF) in 1975 1 and its isolation and characterisation in 1984 2, the 17 kDa secreted form of this molecule has been established as a potent inflammatory cytokine with a myriad of diverse functions across a number of different cell types. Initially discovered as a serum factor which induced cell death in tumour cells 1 and thought at that time to be a promising target as a cancer treatment, TNF was later realised to be a potential target for the treatment of inflammatory diseases, such as rheumatoid arthritis (RA) 3, Crohn’s disease (CD) 4, ankylosing spondylitis (AS) 5, and psoriasis 6. However, localised administration of TNF is used as an effective therapy via isolated limb perfusion in patients with melanoma with multiple in-transit metastases 7. TNF is produced primarily by monocytes/macrophages, but a number of other cell types, such as T and B lymphocytes, mast cells, natural killer cells, neutrophils, fibroblasts, and osteoclasts, can also secrete TNF 8, albeit in smaller quantities. TNF is first produced as a 26 kDa 233-amino-acid transmembrane protein (mTNF) that is expressed on the cell surface, where it either continues to reside or is actively cleaved by TNF-converting enzyme to produce a 17 kDa 157-amino-acid soluble TNF (sTNF) form; sTNF is subsequently released and becomes detectable in the blood plasma 9. mTNF and sTNF both perform cellular functions mediated by either of its two receptors: TNFR1, expressed across all human tissues, and TNFR2, expressed primarily in immune cells, neurons, and endothelial cells 10, 11. mTNF functions as a ligand transmitting cell-to-cell interactions and, when bound to TNFR2 (its primary biological target) 12, is able to induce a more potent response than sTNF; interestingly, mTNF has also been shown to function as a receptor by initiating a cell signalling cascade through outside-to-inside signalling 13. TNFR1 and 2, though similar in their extracellular structures at the mTNF- and sTNF-binding sites, have distinct intracellular structures which bind to a number of adaptor proteins 14. TNFR1’s cytoplasmic tail contains a death domain (DD), thereby allowing it to recruit the TNFR1-associated DD (TRADD) 15; TNFR2, on the other hand, does not have an intracellular DD and recruits the TNFR-associated factor (TRAF) 1 and 2 proteins instead ( Figure 1) 16. Whereas both TNFR1 and 2 signalling pathways may lead to the activation of nuclear factor-kappa B (NF-κB) and the induction of a cell survival response, TNFR1 is also capable of inducing a cell death response depending on prevailing physiological circumstances; however, the regulation of the two TNFRs is dependent on the cellular environment and is not fully understood ( Figure 1) 17. The past decade has seen remarkable progress in the elucidation of regulatory cross-talk between TNFR1 and 2 as well as the individual but complementary functions of these two pleiotropic receptors 18, 19. [Figure: Overview of tumour necrosis factor (TNF): TNF receptor 1/2 (TNFR1/2) signalling pathways.Both soluble TNF (sTNF) and membrane TNF (mTNF) activate TNFR1. TNFR1 contains a death domain which interacts with TNFR1-associated death domain (TRADD). Depending on the ubiquitination state of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), the cell undergoes apoptosis (via complexes IIa and IIb), necrosis (via complex IIc), or cell survival (via complex I). The formation of complexes IIa and IIb leads to the cleavage of pro-caspase-8 to form caspase-8 and induction of apoptosis. When complex IIc forms, the mixed lineage kinase domain-like protein (MLKL) is activated, inducing necroptosis. Upon the formation of complex I, cell survival is induced via the activation of nuclear factor-kappa B (NF-κB) and AP1 transcription factors because of RIPK1 ubiquitination. TNFR2, however, is activated primarily by mTNF and does not contain an intracellular death domain but interacts directly with TNFR-associated factor (TRAF) 1 and 2 to induce the formation of complex I with induction of homeostatic signals.] Upon binding of TNF to TNFR1, TNFR1 undergoes a conformational change in its DD, whereby both TRADD and receptor-interacting serine/threonine protein kinase 1 (RIPK1) are recruited, leading to the formation of complex I and the initiation of cell survival via activation of the NF-κB pathway ( Figure 2) 20– 22. TNF-mediated cell death is highly dependent on various cell death check points, which regulate the pro-survival pathway; when these check points are disrupted, TNF-mediated signalling occurs through the formation of complexes IIa, IIb, and IIc 23. The ubiquitination status of RIPK1 is a critical determinant of whether a particular signalling pathway promotes cell survival, through complex I 24, apoptosis (controlled cell death), via complex IIb 25, 26, or necrosis (uncontrolled cell death), through complex IIc 27, 28. [Figure: Overview of the tumour necrosis factor receptor 1 (TNFR1) signalling pathway.In the binding of TNF to TNFR1, TNFR1 recruits the TNFR1-associated death domain (TRADD), which then binds to receptor-interacting serine/threonine-protein kinase 1 (RIPK1), TNFR-associated factor 2 or 5 (TRAF2/5), and cellular inhibitor of apoptosis protein 1 or 2 (cIAP1/2) to form complex I. cIAP1/2 and the linear ubiquitin chain assembly complex (LUBAC), consisting of HOIP, HOIL, and SHARPIN, add Met1-linked and Lys63-linked polyubiquitin chains, respectively, to RIPK1. This stabilises RIPK1, amplifying its signal. Lys63-linked chains on RIPK1 recruit the transforming growth factor-beta (TGFβ)-activated kinase 1 (TAK1) complex, consisting of TGFβ-activated kinase 1 and mitogen-activated protein kinase (MAPK)-binding protein 2 and 3 (TAB2 and 3) and TAK1. The TAK1 complex phosphorylates MAPK, Jun N-terminal kinase (JNK), and the IκB kinase (IKK) complex. This results in the translocation of transcription factors AP1 and nuclear factor-kappa B (NF-κB) into the nucleus, leading to the transcription of target genes. RIPK1 is deubiquitinated by cylindromatosis tumour suppressor protein deubiquitinase (CYLD), facilitating its dissociation from complex I to form complex IIb, consisting of RIPK1, RIPK3, FAS-associated death domain (FADD), caspase-8, and FLICE-like inhibitory protein long (cFLIP L). cFLIP L regulates both the apoptosis and the necrosis pathway, preventing caspase-8 activation to avert apoptosis. cFLIP L acts in complex with caspase-8 to cleave RIPK1 and RIPK3 to inhibit their aggregation and the activation of mixed lineage kinase domain-like protein (MLKL), which would